U.S. regulators are trying to shut down the industry for compounded weight-loss drugs, which could result in higher costs or ...

Telehealth providers, whose revenue skyrocketed amidst GLP-1 shortages, remain defiant on their compounded semaglutide ...

Two common GLP-1 medications that are approved by the Food and Drug Administration (FDA) specifically for weight loss are ...

We came across a bullish thesis on Novo Nordisk A/S (NVO) on Substack by Felix. In this article, we will summarize the bulls’ ...

which has asked for a ban on other parties making copies of its tirzepatide-based therapies Mounjaro for diabetes and Zepbound for obesity, as well as dozens of legal challenges from Novo Nordisk ...

Novo Nordisk, the maker of Ozempic and Wegovy, has also jumped into the legal fight —this time by intervening in the OFA’s lawsuit against the FDA. The company supports the agency’s move to restrict ...

Pfizer’s announcement that it will stop developing its oral weight-loss drug gave shares of Wegovy maker Novo Nordisk and ...

The UK Supreme Court is set to rule on a legal challenge concerning the definition of 'woman' under equality laws, a dispute between For Women Scotland and the Scottish government. The core of the ...

LONDON (AP) — The U.K. Supreme Court is poised to rule Wednesday in a legal challenge focusing on the definition of a woman in a long-running dispute between a women’s rights group and the ...

Shares of weight-loss drugmakers Novo Nordisk A/S and Eli Lilly and Co. got a nice lift Monday, after a potential competitor decided to cancel development of its GLP-1 obesity drug. “We continue ...

NLR does not answer legal questions nor will we refer you to an attorney or other professional if you request such information from us. Under certain state laws, the following statements may be ...